pharma · Obesity · Obesity With Diabetes · KLRA
Kailera Therapeutics
Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker KLRA. Primary therapeutic focus areas include Obesity, Obesity With Diabetes. NovaPharmaNews links 7 clinical pr
Waltham, USA HQ
2024 Founded
153 Employees
Public company Type
KLRA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2024
- Employees
- 153
- Programs
- 7
- Drugs
- 3
- Patents
- 0
KAI-9531
Phase 3 · small molecule · Obesity With Diabetes
KAI-9531 for Obesity With Diabetes is a Phase 3 program (small_molecule) at Kailera Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code K9531-3104
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Kailera Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Obesity With Diabetes
- Status
- active
- Trials
- 1